Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY3954068 · 1 trial · 1 indication
A summary of AEs, TEAEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the reported adverse events module
A summary of AEs, TEAEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the reported adverse events module
| Arm | Type | Description |
|---|---|---|
| LY3954068 (Part A) | EXPERIMENTAL | Single ascending dose of LY3954068 administered intrathecally (IT) |
| Placebo (Part A) | PLACEBO_COMPARATOR | Single ascending dose of placebo administered IT |
| LY3954068 (Part B) | EXPERIMENTAL | Multiple ascending dose of LY3954068 administered IT |
| Placebo (Part B) | PLACEBO_COMPARATOR | Multiple ascending dose of placebo administered IT |
| Name | Type | Description |
|---|---|---|
| LY3954068 | DRUG | Administered IT |
| Placebo | DRUG | Administered IT |
| Flortaucipir F18 | DRUG | Administered intravenously (IV) prior to Positron Emission Tomography (PET) scan |
Inclusion Criteria: * Have a body mass index (BMI) within the range 18 to 40 kilograms per square meter (kg/m²), inclusive, at screening. * Have gradual and progressive change in memory function for greater than or equal to (≥) 6 months as reported by the participant or informant. * Have a mini men...
Top 20 of 30 competitors
LY3954068 is an investigational small molecule drug being developed by Eli Lilly and Company for Alzheimer disease. It is in Phase 1 clinical development and is being studied in participants with early symptomatic Alzheimer disease. LY3954068 has not been approved by the FDA and remains in clinical testing.
LY3954068 is being studied as a treatment for early symptomatic Alzheimer disease. Its only disclosed clinical trial enrolls participants aged 50 years and older with early symptomatic Alzheimer disease, and it is not being tested in healthy volunteers. The drug is investigational and has not been approved for any use.
LY3954068 is being developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. Lilly is the sponsor of the first-in-human Phase 1 study of the drug in early symptomatic Alzheimer disease.
LY3954068 is in Phase 1 clinical development. Its single trial is a first-in-human Phase 1 study that is currently recruiting. The drug is investigational, and no Phase 2 or later-stage trials have been completed.
LY3954068 is being studied in one clinical trial, NCT06297590, titled a first-in-human study of LY3954068 in participants with early symptomatic Alzheimer's disease. The Phase 1 trial is recruiting 56 participants across the United States, Japan, and the United Kingdom, and it is randomized, double-blind, and placebo-controlled.
No. LY3954068 is an investigational drug in Phase 1 clinical development and has not been approved by the FDA. It is being evaluated in a single first-in-human study in early symptomatic Alzheimer disease, and its safety and efficacy have not been established.